Market Definition 

Recombinant proteins are designed by transfecting foreign genes into a host cell. It is used to produce pharmaceutical products, antibodies and enzymes for disease treatment, protein-based polymers for drug delivery, protein scaffolds for tissue engineering, and for a myriad of other uses. 

Global recombinant protein market was valued at $XX million in 2019 with a CAGR of 6.6% from 2020 to 2026. 

Market Dynamics 

Technological advancement in recombinant protein production is driving the market. For instance, Lonza has expanded its cell culture media portfolio with the GSv9 Media and Feeds, providing a fully integrated solution designed to optimize recombinant protein production using Lonza’s GS Gene Expression System. The new animal-component free media and feeds are intended to be easy to implement, highly robust and enable greater batch-to-batch consistency. The biopharmaceutical manufacturers develop streamlined and scalable bioproduction processes. Additionally, iBio, Inc. has introduced the FastGlycaneering Development Service, which includes a new glycosylation technology for engineering high-performance recombinant proteins. The Biopharmaceutical and biosimilar producers can take advantage of low-cost afucosylation controls, oligomannose modification capabilities, and more custom glycosylation techniques using iBio’s plant-based manufacturing platform to rapidly develop high-quality biobetters, novel antibody therapeutics, and biosimilars. However, safety issues regarding recombinant protein might hamper the market growth. The production of recombinant protein in large scale using E. coli, cause several problems including endotoxin and bad smell. Moreover, increasing research and development expenditure on biologic drugs would provide lucrative opportunities for the market in coming years. 

Market Segmentation 

The global recombinant protein market is mainly classified based on product type, application, and end user. Product Type is further segmented into Hormones, Plasma Protein Factor, Immune Checkpoint Regulators, Recombinant Metabolic Enzymes, Growth Factors, Cytokines, and Others. By application the market is divided into Biopharmaceutical Production, Basic Research, Drug Discovery & Development, and Others. By end user the market is further divided into Academic & Research Institutes, Biopharmaceutical Companies, Contract Research Organizations, and Others. 

Based on the product type, Immune Checkpoint Regulators has shown significant growth in 2019, owing to the commercialization of recombinant protein products, increasing clinical studies for recombinant protein products and strategic partnership between companies to commercialize recombinant protein. For instance, CStone and EQRx has entered into a global strategic partnership for two immune checkpoint inhibitors including sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1). The partnership offers the clinical as well as the commercial potential of sugemalimab and CS1003. Sugemalimab is an investigational anti-PD-L1 monoclonal antibody. CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) developed for immunotherapy of various tumors. 

Regional Analysis 

Based on geography, the global recombinant protein market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa. 

North America was dominating the recombinant protein market in 2019, due to the technological advancement in recombinant protein production, rising investment for the development of recombinant protein product, and strategic partnership between companies to develop recombinant protein. For instance, Crown Bioscience, a subsidiary of Crown Bioscience International and a global drug discovery and development services company, has introduced six new recombinant cell lines for biological studies and drug screening and development. These recombinant cell lines express enzymes and proteins that impact immune response, cell proliferation and cell death. 

Competitive landscape 

Key players operating in the recombinant protein industry include AMSBIO, Abcam plc, Bio-Rad Laboratories, Inc., Merck Millipore Limited, Thermo Fisher Scientific, Inc., BPS Bioscience Inc., PerkinElmer, Inc, GenScript Corporation, Crown Bioscience, Inc., and Sanofi SA. 

The strategic acquisition between companies to expand its market presence, launch of recombinant protein product, rising investment for the development of recombinant protein, and increasing clinical studies in recombinant protein products are some of the strategies adopted by the major companies. For instance, on September 3, 2020, Sanofi and GSK has conducted Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership with Sanofi and GSK, uses the same recombinant protein-based technology of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology. The Phase 1/2 clinical trial is designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the COVID-19 vaccine candidate. 

Recombinant Protein Market Key Segments: 

By Product Type 

• Hormones 
• Plasma Protein Factor 

• Immune Checkpoint Regulators 
• Recombinant Metabolic Enzymes 
• Growth Factors 
• Cytokines 
• Others 

By Application 

• Biopharmaceutical Production 
• Basic Research 
• Drug Discovery & Development 
• Others 

By End User 

• Academic & Research Institutes 
• Biopharmaceutical Companies 
• Contract Research Organizations 
• Others 

Key Global Recombinant Protein Industry Players 

• AMSBIO 
• Abcam plc 
• Bio-Rad Laboratories, Inc. 
• Merck Millipore Limited 
• Thermo Fisher Scientific, Inc. 
• BPS Bioscience Inc. 
• PerkinElmer, Inc 
• GenScript Corporation 
• Crown Bioscience, Inc. 
• Sanofi SA 

What Report Provides 

• Full in-depth analysis of the parent Industry 
• Important changes in market and its dynamics 
• Segmentation details of the market 
• Former, on-going, and projected market analysis in terms of volume and value 
• Assessment of niche industry developments 
• Market share analysis 
• Key strategies of major players 
• Emerging segments and regional growth potential